Genovis Has Signed A Strategic Cooperation Agreement With Alphalyse Inc.

The cooperation agreement will provide Genovis with access to Alphalyse’s expertise in mass spectrometry while Alphalyse will have the opportunity to offer its customers analyses based on Genovis’ unique enzymes for antibodies and other pharmaceutical proteins.

Much of Genovis’ customer base works with mass spectrometry in the analysis of biologics. Genovis and Alphalyse will actively market new methods based on Genovis’ products, which directly focus on this customer group. This strategy will strengthen Genovis, which will be able to expand its customer base and thus increase sales.

“Alphalyse has world-leading expertise in mass spectrometric analysis of proteins. Their knowledge of sample processing and the limitations of current enzymes enable us to use existing and upcoming products in applications where they will have maximum value. We are very pleased to have the opportunity to market and develop methods of mass spectrometric analysis together with Alphalyse and I am convinced that this will be a long-term and mutually rewarding collaboration,” says Fredrik Olsson, CEO of Genovis.

“Genovis has unique enzymes and products that allow for better and faster analysis of protein-based drugs when using mass spectrometry. The collaboration with Genovis provides Alphalyse with a major advantage in our work helping pharmaceutical companies that develop products such as monoclonal antibodies, antibody drug conjugates for cancer treatment and de-novo-sequencing of new antibodies in the discovery phase,” says Ejvind Mørtz, COO of Alphalyse.


Alphalyse is a contract research company (CRO) with cutting-edge expertise in mass spectrometry-based protein analysis for research, production and clinical development of native and recombinant proteins. Through its PICK 'n POST™ protein analysis services and customized analytical services, the company offers a range of unique high-quality protein analyses to identify and characterize biopharmaceutical proteins such as monoclonal antibodies and vaccines. The services are used by the biotech industry, pharmaceutical companies and academic research groups worldwide. Alphalyse has offices in Odense, Denmark and Palo Alto, California, USA.


Genovis’ products are marketed under the name “Smart Enzymes” and are used to process antibodies and split them into smaller fragments. To date, the products have been marketed primarily for characterization of biologics. Customers use small quantities of the products in a large number of samples to divide the drug candidate into smaller fragments, which are then analyzed. All of the products are also highly effective in production of large quantities of antibody fragments, which are required in several different studies in preclinical drug discovery.

For more information, please contact: Fredrik Olsson, CEO, Genovis AB Tel: 0046 (0)46 -101233

The Group consists of Genovis AB and the wholly owned subsidiary Genovis Inc. (USA).

Back to news